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Background:Kidney disease (lupus nephritis [LN]) constitutes a feature of systemic lupus 
erythematosus (SLE)  in up to 50 - 70% of patients with the disease. Although most LN 
patients are suitable for renal transplantation when they develop end stage renal 
disease (ESRD), the risk of recurrence of LN post-transplantation can be as high as 30%. 
Since the outcomes of renal transplantation in ESRD-LN patients has not been 
adequately studied in South Africa, the present study aims to retrospectively explore 
the aforementioned objective in a single centre. 
Methodology: The study was designed as a retrospective descriptive study of patients 
with LN transplanted in the renal unit of Groote Schuur Hospital, Cape Town from 
1stJanuary 2004 to 31stDecember 2013.  
Results: There were 454 patients who were transplanted in the study period of which 
15/454 (3.3%) had LN. The M:F ratio of LN patients was 1:14, mean age was 25±10 
years, all were known with class- IV LN and 10/15 (66.7%) received graft from a 
cadaveric donor. Immunosuppression was initiated in 7/15 (46.7%) with combination of 
cyclosporine and azathioprine; in 2/15 (13.3%) with tacrolimus and azathioprine and in 
6/15 (40.0%) with Tacrolimus and MMF. All patients received corticosteroids. 
Recurrence of LN was seen in one patient (6.7%) who developed class V LN. Graft 
rejection was diagnosed in 10/15 cases (66.7%) with types of rejection noted to be 
acute cellular rejection in 6/15 (40%), antibody mediated rejection 1/15 (6.7%) and 
chronic rejection in 3/15 (20%). ESRD occurred in 3 patients (20%) with causes from 
antibody mediated rejection (6.7%), chronic allograft nephropathy (6.7%) and renal 
artery thrombosis (6.7%). Mean time to ESRD was 16.0 months. Five deaths (33.3%) 




ESRD after non-acceptance to the chronic dialysis program; 1/15 (6.7%). Mean time to 
death was 44.1 months.  
Conclusion: This study shows that recurrence of LN in the graft kidney is uncommon in 
South Africa. However, effort to reduce high rates of rejection and improve graft and 












































Systemic lupus erythematosus (SLE), commonly known as Lupus, is an autoimmune 
connective-tissue disorder with a wide range of systemic involvement (1). Various 
mechanisms have been proposed in the stimulation of autoantibodies production 
against ubiquitous self-antigens, including abnormal clearance of apoptotic material (2). 
While there are considerable variations in disease incidence, differences in disease 
prognosis and activity exists based upon the race and ethnicity.Renal involvement 
known as Lupus nephritis (LN) continues to be the major cause of morbidity and 
mortality in SLE patients (3-7). Approximately 10% of patients with SLE, willin due course 
develop end-stage renal disease (ESRD) or undergo renal transplantation as a treatment 
option(8).  
The kidney is the most commonly involved visceral organ in SLE as urinalysis of 
asymptomatic patients often shows hematuria and proteinuria and 50% of patients 
could also develop overt abnormal renal function (9-10). SLE affects people from every 
part of the world and has been shown to be about nine times as common in females as 
in males. Furthermore, the cumulative incidence of LN has been reported to be higher in 
Asians (55%), patients of black African descent (51%) and Hispanics (43%) in comparison 
to Caucasians (14%) (11-16).  
The aim of this study is to document the outcome of ESRD patients with LN who 
received a kidney transplant at a single centre in Cape Town. There are no reports of 
outcome studies on LN patients who have been transplanted from South Africa. 
Although this study is focused on the outcome of kidney transplanted patients with LN, 
it is relevant to present some context by providing a brief overview of the pathogenesis, 
classification, diagnosis and treatment approaches to LN in order to maximize our 
understanding of the outcomes of renal transplant patients with LN. 
Pathogenesis of LN 
The pathogenesis of LN involves various extra-renal and intra-renal pathogenic 
mechanisms. While extra-renal mechanisms involves immune intolerance to nuclear 




alpha(IFN-α)signalling, dendritic cells, T helper cells, B cells and plasma cells response, 
the intra-renal aetiology involves antibody binding to multiple intra-renal autoantigens, 
tertiary lymphoid tissue formation, localized antibody production and intra-renal 
complement activation (17). 
 
Extra-Renal Pathogenic Pathways 
SLE involves compromised cell death mechanisms such as mutations in apoptosis and 
delayed apoptotic cell clearance through opsonisation by complement proteins and 
their removal by phagocytosis (18-19). The delay in clearance of apoptotic cells leads to 
the incomplete degeneration of nuclear components by the immune system thereby 
stimulating production of anti-nuclear antibodies (20). Further, this pseudo anti-viral 
immune mechanism also triggers the antigen presenting cells, specifically dendritic and 
B cells which secretes large amount of type I IFNs exaggerating the anti-viral immune 
response. In-extension, hyper stimulation of antigen presenting cells results in the 
aberrant proliferation of B and T lymphocytes which turns to be autoreactive 
lymphocytes producing several autoantibodies in SLE (21) (Figure 1).  
Several environmental factors have been reported to trigger SLE activity. While viral 
infections stimulate release of IFN-alpha thereby triggering antiviral immunity and lupus 
disease activity, bacterial infections stimulate nonspecific immune response involving a 
transient production of autoreactive lymphocyte clones (22). Additionally, bacterial 
products stimulate intra-renal immune cells and renal cells with consequent 
exacerbation of proteinuria and kidney damage. Ultraviolet light also act as an 
environmental trigger of SLE activity by enhancing the number of apoptotic cells due to 
keratinocytes cell death (23). Intake of certain drugs can also act as SLE inducer by 
inhibiting methyl-transferases resulting in the unmasking of endogenous nucleic acids 
and up-regulation ofToll Like Receptor7and 9(TLR7,TLR9) (24, 25). Hormones like, 
progesterone and estrogens also triggers the sex hormone-dependent immune-






Figure 1: Extra-renal pathogenic mechanisms of LN (From Lech & Anders, J Am 























A) Cell Death and Dead Cell Mechanisms  B) Induction of Anti-viral Immunity C) 







Intra-Renal Pathogenic Pathways 
 
Among the several intra-renal mechanisms, immune complex-mediated renal damage is 
reported to play considerable role in LN. Studies have shown that circulating immune 
complexes passively deposit in the mesangium, sub endothelial, sub epithelial spaces or 
in peritubular capillaries giving rise to class I and II lesions, class III and IV lesions, class V 
lesions, and overlapping III/IV and IV/V lesions respectively depending on the severity of 
LN (27,28). However, the disease development is not restricted to the deposition of 
circulating immune complexes as various studies expressed the formation of in situ 
immune complexes within the glomerulus due to the secondary binding of nucleosomes 
generated from renal cells with circulating antibodies (29). Further, these intrarenal 
immune complexes activate the complement system which is genetically compromised 
in SLE patients, complement   stimulate immune complex–related renal inflammation, 
overalldeposition of sub-epithelial immune complexes results in secondary 
membranous GN and nephrotic syndrome by damaging podocytes(30,31,32). 
In-addition, circulating immune complexes triggers intrarenal inflammation through 
TLRs present in macrophages and dendritic cells which in turn produce significant 
amount of pro-inflammatory cytokines, IFN-alpha and IFN-beta (33-35). activated IFN 
signalling further attributes to renal damage by triggering the formation of 
tubuloreticular structures or inclusions, one of the hallmarks of LN (36, 39).  
LN is characterised by the invasion of Cytotoxic T cells, Th17 T cells, as well as B cells 
(40). Different chemokine family members like CCL2, place CCR2+ proinflammatory 
macrophages and T cells into the glomerulus and tubulointerstitium (41,42). These 
infiltrating leukocytes were reported to form de novo perivascular tertiary lymphoid 
organs inside the kidney, which provide environment for clonal expansion, proliferation 
and activation of B cells in proximity to T cell aggregates (43).The proliferating B cells 
produces local inflammation, tissue pathology and autoantibody production (44,45,46). 




complex mediated renal damage which further exacerbates the renal pathology. It is 
reported that the healing response initiates focal tuft necrosis followed by the 
deposition of extracellular matrix over migrating parietal epithelial cells in the 
glomerular tuft and Bowman’s space resulting in global glomerulosclerosis, also referred 
to as class VI LN (47).  
Diagnosis and Classification of LN 
According to the Systemic Lupus International Collaborating Clinics Classification (SLICC) 
criteria, LN is clinically diagnosed when a patient with SLE showed persistent proteinuria 
(>0.5 g/24 h) or cellular red cell casts (48). Further, Lupus Nephritis has also been 
classified based on the histological features assessed in renal biopsy, as per the 
standards established by the International Society of Nephrology (ISN) and Renal 
Pathology Society (RPS) in 2003 (49). The main histological manifestation of LN is 
immune complex mediated glomerulonephritis which manifests clinically as 
asymptomatic proteinuria, hypertension, microscopic hematuria, active urinary 
sediments, nephritic syndrome, and progressive renal failure (15,16).Based on the 
glomerular pathology, ISN/RPS system has classified LN in 2003 as indicated in Table 1 
(49). 
Table 1: Classification of Lupus Nephritis as per ISN/RPS, 2003. 
Disease class Description 
Class I Minimal mesangial lupus glomerulonephritis (LGN) 
Class II Mesangial proliferative LGN 
Class III Focal LGN (<50% of the total number of glomeruli): 
 III (A) Purely active: focal proliferative LGN 
III (A/C) Active and chronic  
III (C) Chronic: focal sclerosing LGN 
Class IV Diffuse segmental (IV-S) or global (IV-G) LGN (50% or more of 




 IV-S (A) or IV-G (A): diffuse segmental or global proliferative 
LGN IV-S (A/C) or IV-G (A/C) 
 IV-S (C) or IV-G (C): diffuse segmental or global sclerosing LGN 
Class V Membranous LGN 
Class VI Advanced sclerotic LGN (>90% of glomeruli globally sclerosed 
without residual activity): end stage LGN 
 
 Class II and Class V patients have a weak response to renal function over long time 
periods under observation (50). However, patients with Class III and Class IV have more 
serious disease progression. Proliferative form of LN, which include class III, class IV and 
mixed class V occur more as compared to other forms.Moreover, renal biopsies were 
scored for their activity and chronicity implicating reversible or irreversible lesions 
respectively. The activity index (AI) was scored at the scale of 0 to 24 obtained as the 
sum of six histologic features-endocapillary proliferation, infiltration of glomerular 
leukocytes, wire loop deposits, fibrinoid necrosis, and karyorrhexis, cellular crescents 
and interstitial inflammation, each of which can be individually scored as 0 to 3+. 
Similarly, chronicity index (CI) was score at the scale of 0 to 12, obtained as the sum of 
glomerulosclerosis, fibrous crescents, tubular atrophy, and interstitial fibrosis, each of 
which can be individually scored as 0 to 3+. An AI >7 and CI>3 indicates poor long term 
outcomes in lupus nephritis (28,51,52,53,54). 
 
Treatment  
The treatment of LN broadly follows a bi-phasic patterni.e. induction and maintenance 








Figure 2: Treatment strategies of patients with Lupus Nephritis (From Okpechi et al. 
SAMJ.2015Dec;105(12):1071)
APLS = antiphospholipid syndrome;AZA = azathioprine; ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor 
blocker; CNI = calcineurin inhibitor; CS = corticosteroid; CYC = cyclophosphamide; DVT = deep-vein thrombosis; MMF = 
mycophenolate mofetil; CV = cardiovascular). 
* Immunosuppression to be dictated by extrarenal manifestations. 
† PaUents should be prepared for renal replacement therapy (dialysis/ transplantation). 
 
Treatment of ISN Class I and II LN 
Usually patients with ISN class I and II LN did not seek renal directed therapy rather the 
clinical conditions can be maintained using conservative non-immunomodulatory 
therapeutics. Use of anti-hypertensive therapy like angiotensin-converting enzyme 
(ACE) inhibitors or angiotensin receptor blockers has been recommended as the first-
line of treatment (56). These drugs act upon renin angiotensin aldosterone system 
(RAAS) by decreasing intra-glomerular pressure, systemic arterial BP, urinary protein 





Induction therapy for Class III and IV LN: 
 
Patients with Class III and IV LN were usually subjected to three consecutive pulses of 
intravenous methylprednisolone (500 – 750 mg daily) in association with 
immunosuppressive agents: cyclophosphamide (CYC) (daily oral or monthly intravenous 
pulse therapy) or mycophenolate mofetil (MMF). Continued treatment with oral 
prednisone (1mg/kg/day) after pulse treatment with methylprednisolone is 
recommended. In addition, other agents has also been explored in induction therapy 
regimen like Rituximab, an anti-CD20 monoclonal antibody that depletes B cells, 
calcineurin inhibitor with MMF or azathioprine plus corticosteroids, however these 
treatment strategies need extensive clinical trials (59, 60).  
 
Maintenance and adjunctive therapy for proliferative LN: 
 
In this phase, induction phase treatment is de-escalated in order to reduce the 
progression of chronic kidney disease. The main objectives of continued 
immunosuppressive therapy are to inhibit relapse and flares of disease activity leading 
to chronic irreversible renal scarring as well as to prevent chronic adverse effects of 
therapy. While immunosuppressive agents like MMF, azathioprine (AZA) and 
corticosteroids remains the ideal choice, calcineurin inhibitors are administered in 
special circumstances where patients exhibit intolerance to MMF and AZA or persistent 
heavy proteinuria (55).   
Adjunctive therapies are commonly initiated at the Induction phase; however their 
continuation or discontinuation depends on the disease conditions. Several adjunctive 
therapies have been recommended in Lupus Nephritis treatment including RAAS 
inhibition for proteinuria and blood pressure treatment, osteoporosis treatment by 




low-dose acetylsalicylic acid for antiphospholipid syndrome patients, anticoagulant for 
nephrotic syndrome patients and isoniazid for tuberculosis prophylaxis (55). 
 
Treatment of ISN Class V LN: 
 
MMF with or without calcineurin inhibitors has been reported to be potentially useful 
treatment for Class V LN. Other treatment options include oral cyclosporine or 
tacrolimus course, monthly intravenous pulses of cyclophosphamide, oral MMF, or oral 
azathioprine in combination with corticosteroids (55,61). 
 
Treatment of Class VI LN: 
 
Advanced LN is often recommended for renal replacement therapy like haemodialysis, 
peritoneal dialysis or transplantation.  
Challenges in the Management of Lupus Nephritis  
Some researchers shown that there are some negative misconceptions which can affect 
the treatment strategy for Lupus Nephritis. However, it has been suggested that the 
outcome of LN patients could be improved if these misconceptions are addressed, The 
following are ten common mistakes they have observed surrounding the management 
of patients with lupus nephritis, which seriously affect the lupus treatment (83). 
1.Assuming intravenous cyclophosphamide as gold-standard for lupus nephritis 
induction therapy.  
2.Inappropriate dosage regimen of corticosteroids.  
3.Infrequent use of antimalarial agents.  




5.Improper scaling of immunosuppression treatment intensity in class V membranous 
lupus and other classes of lupus nephritis.  
6.Discontinued treatment by patients on treatment failure.  
7.Inappropriateuse of immunosuppressive agents in patients with advanced kidney 
disease.  
8.Avoiding monitoring of adverse effects of immunosuppressive agents and using 
prophylaxis.  
9.Unnecessary biopsy undertaking from high-risk patients considering the patient’s non-
responsive for therapy at advanced stage.  
10.Poor decision making regarding treatment in the pregnant lupus patient.  
Lupus Nephritis: Data from South Africa 
Data from South Africa shows that LN is the most frequent secondary glomerular 
disease (39.0%) and a common cause of the nephrotic range proteinuria (17.2%) (84). In 
a retrospective study conducted by Ayodele et al in 2013, 50% of LN patients developed 
ESRD in South Africa with survival rate of 54, 34 and 27 % at 5-, 10and 15-year 
respectively (85). A recent systematic review reported the disease and treatment 
outcomes in LN patients from studies conducted in Africa (86). The study highlighted a 
clear paucity of multicenter studies in South Africa pertaining to LN due to poor 
infrastructure, excessive procedural costs, lack of skilled nephrologists, and difficulties in 
performing diagnostic renal biopsies (86, 87, 88) 
End Stage Renal Disease (ESRD) and kidney transplantation 
According to the records of John Hopkins Lupus Cohort, approximately 15% patients of 
Systemic Lupus Erythematous (SLE) developed ESRD within ten years of disease tenure 




non-lupus ESRD patients, suggesting that they could be excellent candidatesfor renal 
transplant therapy (62,63). Studies have also shown that with the development of ESRD, 
the SLE disease symptoms become quiescent, however the exact relationship between 
the two largely remains misunderstood(64).  
Prior to renal transplantation, ESRD-LN patients were subjected to dialysis (hemodialysis 
or peritoneal) and studies reported an overall good survival rate for at least five years 
(62,65,66). However, infections, cardiovascular disorders and history of anti-
phospholipid antibody (aPL) syndrome continue to be life-threatening factors within 
three months of dialysis (67). Overall, the choice to undertake dialysis prior to kidney 
transplantation incur several benefits like suppression of any residual lupus activity, 
dormancy of disease symptoms, and recovery of renal functioning in patients with 
rapidly progressive glomerulonephritis due to LN(65,66,67). 
Although renal transplantation is an accepted form of therapy for LN patients with 
ESRD, several critical issues arises perhaps due to the presence of extra-renal 
complications either because of disease or immunosuppressive therapy.  Among several 
issues, the key concern is the recurrence of LN in the transplanted kidney. The incidence 
of recurrent LN in kidney transplant recipients has been reported to vary between 2-
11%(68,69,70,71). Multiple studies identified a series of risk factors associated with the 
loss of allograft in lupus patients such as race (black African ancestry), gender (female), 
young age, presence of antiphospholipid autoantibodies, and kidney acceptance from 
living donors (72-76).  
Kidney transplantation Outcomes in ESRD-LN patients 
Renal transplantation in ESRD secondary to LN is believed to be associated with 
generally good outcomes, comparable with transplant outcomes in non-lupus ESRD 
patients. In a study by Stone et al, the allograft survival rate was found to be inferior in 
six out of ten cases in SLE patients when compared with comparison groups, while the 
remaining four cases expressed equivalent outcomes (77). Similar results were found in 




survival allograft rate in transplant recipients from living donor than the cadaveric donor 
(78).The poor renal transplantation outcomes among SLE patients were largely 
attributed to the risk of recurrent lupus nephritis in the allograft and the presence of 
antiphospholipid autoantibodies (77).Table 2 demonstratesthe clinical outcomes of 
kidney transplants in patients with chronic kidney diseases secondary to LN, polycystic 
kidney disease and diabetes nephropathy (79).The study outcomes revealed equivalent 
graft and patient survival success rates in kidney transplant patients with end stage 
renal disease secondary to lupus nephritis and other kidney diseases. Further, the study 
results demonstrate substantially low occurrence of complication rate and risk of 
recurrence for lupus nephritis (79).  
Table 2: Clinical outcomes of kidney transplants in patients with ESRD due to LN, and 
other kidney diseases(79). 
Total Patients Lupus Nephritis Polycystic Kidney 
Disease 
Diabetes Nephropathy 
N=136 27 (19.9%) 31 (22.8%) 78 (57.4%) 
Graft Survival 
1st Year 96.3% 90% 91.7% 
3rd Year 82.5% 86% 80.3% 
5th Year 82.5% 76.5% 67.9% 




Better renal transplantation outcomes were reported in a single-centre cohort study 
that included 40 SLE renal transplantation patients.Graft failure was noticed in 30% 
cases due to allograft nephropathy, acute rejection, and humoral rejection mediated by 
positive anti-HCV antibodies and an overall patient survival rate of 91.4% was reported 
(80). Another single centre study from Brazil of 13 lupus renal transplant patients 




respectively(81). One patient died with no occurrence of LN in any of the patients, 
suggesting renal transplantation as better alternative therapy in ESRD-LN patients 
(81).Finally, a study from the Gdansk Transplantation Centre demonstrated the survival 
rate of 89.4% (17 of 19) at ten years of follow up and showed that presence of 
antiphospholipid autoantibodies was a negative predictive factor of allograft survival 
(82).  
Recurrence of lupus nephritis in the graft kidney 
Reviews of published reports have shown a rate of clinically recurrent disease in the 
renal transplant of 2.0 to 9.0 percent in patients with lupus nephritis, which is thought 
to reflect diminished immunologic activity (94,72). The incidence of recurrent symptoms 
of systemic lupus was also low at 5.7 percent (94). 
However, higher rates of recurrence of nephritis in the renal transplant have been 
reported in subsequent studies (76). In one study, of 44 patients with lupus, 41 
underwent transplant renal biopsy, 3 was indicated and 38 were surveillance biopsies ; 
among those patient’srecurrent lupus nephritis was noted in 22, resulting in a 
recurrence rate of 54 percent. This higher incidence may be due to the increased use of 
allograft biopsies because the majority of cases were subclinical (76). 
The frequency of recurrence was analyzed using data from the United Network for 
Organ Sharing files (72). Among 6850 kidney transplant patients with end-stage renal 
disease due to lupus nephritis, 167 (2.44 percent) had recurrence. Non-Hispanic blacks, 
females and younger recipients (33 years or younger) had increased odds for recurrence 
1.88, 1.70 and 1.69, respectively(72).  
Recurrence of lupus nephritis can occur as early as the first week to as late as 16 years 






Rationale for the current study 
Being a developing country, patients in South Africa with irreversible renal failure have 
limited access to dialysis facilities due to socio-economic constrains unlike developed 
countries where access to treatment is readily available  to ESRD patients. However, due 
to the presence of cadaveric donor transplant program in South Africa, renal 
transplantation is an affordable alternative option available to the ESRD patients, 
although a huge gap exists between the demand and availability of organs (89-93). 
Hence successful acceptance of allograft is of utmost importance in this part of the 
world. Although few studies have assessed the disease outcomes and prognosis in LN 
patients in South Africa, studies on outcomes of renal transplantation in LN patients 
from South African population is unavailable. The present study aims to investigate the 
outcomes of renal transplantation in a single centre retrospective study conducted at 
Groote Schuur Hospital, Cape Town from 1st January 2004 to 31st December 2013. It is 
hoped that the results of the present retrospective study will increase our 
understanding and improve the outcomes of renal transplant patients with LN in South 
Africa. 
In the next chapter (chapter 2), I have provided in a journal ready manuscript format, 
results of the study conducted to assess patient outcomes. In that chapter, I discuss the 
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OUTCOME OF RENAL TRANSPLANTATION IN PATIENTS WITH LUPUS NEPHRITIS: A 

















Background: Kidney disease (lupus nephritis [LN]) constitutes a feature of systemic lupus 
erythematosus (SLE) in up to 50 - 70% of patients with the disease. Although most LN 
patients are suitable for renal transplantation when they develop end stage renal 
disease (ESRD), the risk of recurrence of LN post-transplantation can be as high as 30%. 
Since the outcomes of renal transplantation in ESRD-LN patients has not been 
adequately studied in South Africa, the present study aims to retrospectively explore 
the aforementioned objective in a single centre. 
Methodology: The study was designed as a retrospective descriptive study of patients 
with LN transplanted in the renal unit of Groote Schuur Hospital, Cape Town from 
1stJanuary 2004 to 31stDecember 2013.  
Results: There were 454 patients who were transplanted in the study period of which 
15/454 (3.3%) had LN. The M:F ratio of LN patients was 1:14, mean age was 25±10 
years, all were known with class- IV LN and 10/15 (66.7%) received graft from a 
cadaveric donor. Immunosuppression was initiated in 7/15 (46.7%) with combination of 
cyclosporine and azathioprine; in 2/15 (13.3%) with tacrolimus and azathioprine and in 
6/15 (40.0%) with Tacrolimus and MMF. All patients received corticosteroids. 
Recurrence of LN was seen in one patient (6.7%) who developed class V LN. Graft 
rejection was diagnosed in 10/15 cases (66.7%) with types of rejection noted to be 
acute cellular rejection in 6/15 (40%), antibody mediated rejection 1/15 (6.7%) and 
chronic rejection in 3/15 (20%). ESRD occurred in 3 patients (20%) with causes from 
antibody mediated rejection (6.7%), chronic allograft nephropathy (6.7%) and renal 
artery thrombosis (6.7%). Mean time to ESRD was 16.0 months. Five deaths (33.3%) 




ESRD after non-acceptance to the chronic dialysis program; 1/15 (6.7%). Mean time to 
death was 44.1 months.  
Conclusion: This study shows that recurrence of LN in the graft kidney is uncommon in 
South Africa. However, effort to reduce high rates of rejection and improve graft and 
patient survival still needs to be studied.  
Introduction 
Lupus nephritis continues to be the most frequent cause of morbidity and mortality 
among patients with systemic lupus erythematosus (SLE) patients and approximately 
40–70% SLE adults show clinical evidence of this renal pathology at presentation (1).  
Approximately 10 to 30 percent of patients with proliferative lupus nephritis progress to 
end-stage renal disease (ESRD), depending upon the disease severity, socioeconomic 
factors, level of treatment adherence, and response to initial treatment (2, 3). Although, 
an overall improvement in disease prognosis has been noticed in recent decades, report 
from the United States Renal Data System from 1995 to 2006 revealed an increase in 
the standardized incidence of ESRD due to lupus nephritis in younger individuals (i.e. 
Age <40 years) (4). 
ESRD due to LN is not a contraindication to renal transplantation, however, extra-renal 
manifestations of SLE (such as multiple thrombosis from anti-phospholipid syndrome) or 
complications of treatment (such as severe opportunistic infections) may pose unique 
challenges. Several studies have reported on risk factors associated with allograft 
rejection in lupus patients including black non-Hispanic origin, female gender, young 
age, presence of anti-phospholipid autoantibodies, kidney acceptance from living 
donors and recurrence of LN in the transplanted kidney (5-9). The risk of recurrence of 
lupus nephritis (RLN) after transplantation may range between 2 and 30% (10). Data 
from the United State Network for Organ Sharing (UNOS) show that out of 6850 kidney 
transplant recipients, RLN was seen in 167 (2.4%) while 1770 (25.8%) experienced at 




Postransplant immunosuppression does not differ from that used routinely; the results 
of kidney transplantation largely depend on the clinical conditions at time of 
transplantation (1).Treatment with new and more potent immunosuppressive drugs 
may improve the outcome of these patients. Further, better survival benefit for ESRD-LN 
patients have been reported for hemodialysis and peritoneal dialysis subjected before 
renal transplantation.  
There are currently no African data reporting on the outcome of kidney transplant 
patients with lupus nephritis. The aim of the present study is therefore to descriptively 
present the outcome of individual LN patients who were transplanted at Groote Schuur 
Hospital from 1st January 2004 to 31st December 2013. The study outcome was non-
composite and defined as any of the following: occurrence of graft rejection, recurrence 




This study was conducted as a retrospective descriptive study of patients, known with 
ESRD secondary to LN who underwent renal transplantation at Groote Schuur Hospital, 
Cape Town from 1st January 2004 to 31st December 2013. The study received ethics 
approval from the joint human research ethics committee of the University of Cape 
Town and Groote Schuur Hospital before commencement (UCT HREC # 
033/2016).Patients’ records were accessed from renal transplant unit database and data 
of transplanted patients with known SLE was selected for the study.  
 
Data collection: 
In this study, we collected data on the demographic and clinical features of patients 
including age, gender, date of birth, date of renal transplantation, date of last follow-up 
visit, class of lupus nephritis, type of renal transplant (cadaveric / living).We also 




delayed graft function following transplant, any rejection post- transplant, serum 
creatinine (and eGFR) on day 1, 30, 90, 365 and last follow- up, immunosuppression 
regimen used (plus any changes during the post- transplant period), trough levels of the 
primary immunosuppression (high / normal / low), renal biopsy post-transplant, any 
recurrence of lupus nephritis, dialysis requirement and death.  
Definitions: 
-ESRD: End-stage renal disease after transplant will be defined as persistent lowering of 
GFR <15ml/min for more than 3 consecutive months whether dialysis requiring or not. 
-Death: All-cause mortality in transplanted patients i.e any cause of death. 
-Duration of follow –up: was defined as the difference between the date of last follow 
up and the date of renal transplant. 
-Duration to ESRD(graft loss/failure): was defined as the difference in the date of 
occurrence of ESRD and date of renal transplant. 
 
-Duration to death: was defined as the difference in the date of death and date of renal 
transplant. 
-Graft rejection: determined only if a graft renal biopsy has been performed and shows 
evidence of cellular or antibody mediated rejection i.e acute or chronic rejection. 
-Recurrence of LN: was defined as present only if a graft renal biopsy shows evidence of 
histological features of LN (i.e proliferative or non-proliferative types of LN with 
presence of mesangial, sub-epithelial or sub-endothelial immune deposits – IgG, IgM, 
IgA or C3) 
Data analysis and Statistics: 
Data analysis was performed with the objectives to a) assess the proportion of patients 




recurrent lupus nephritis in the graft post-renal transplant, and c) determine the period 
prevalence of SLE transplants carried out at Groote Schuur Hospital, Cape Town for the 
study period. The data was analyzed with SPSS (version 22). Frequencies were described 
as percentages and time to death or ESRD was presented in months (median). 
Differences between groups (e.g. males and females or cadaveric and living) was 
additionally analyzed using students’t-test and chi-square statistics.  
Results 
Demographic and transplantation characteristics 
Table 1 provides a summary of the demonstrate the demographic features of the study 
cohort. There were 454 patients who were transplanted in the study period of which 
15/454 (3.3%) had LN. Majority of the patients were females (14/15; 93.3%) with mean 
age at time of kidney transplantation of 25±10 years (Min-Max: 19.2 – 49.1 years). Also, 
there were 3/15 (20%) African and White patients, respectively with majority (60%) 
being coloured. 
All 15 patients were diagnosed with class- IV LN and majority of patients received the 
transplant from a cadaver (66.7%). 
 
Immunosuppressive Treatment Strategies 
 
Table 2 provides summary of immunosuppressive agents used for each patient (initial 
and maintenance), HLA-PRA level at time of transplant and kidney function at day-1 and 
1 year post-transplant. Twelve patients (11/15; 73.3%) had HLA-PRA level of 0%, 2 
patients (13.3%) had PRA level <10% and another 2 patients (13.3%) had PRA level >10% 
but <20%. Only the 2 patients with PRA level >10% received induction therapy with anti-
thymocyte globulin (ATG); all other patients received cyclosporine and 
methylprednisone (with or without Azathioprine as in initialtherapy). For maintenance 




received Tacrolimus and Azathioprine and 40% received Tacrolimus and Mycophenolate 
mofetil.  
 
Renal transplantation outcomes 
 
The assessed outcomes identified in these patients have been summarized in Table 3: 
three patients (20%; #2, #5 and #7) had developed ESRD at the last date of assessment 
within a mean duration of 16 months from time of transplantations (min 15days – max 
2years). All 3 post-transplant ESRD patients subsequently died during follow-up.One-
year and 5-year graft survival was 93.3% and 80% respectively. Overall mortality in this 
cohort was 5/15 (33.3%) with cause of death identified as: sepsis in 3/5 (60%; #2; #3and 
#7), pulmonary embolism in 1/5 (20%; #14) and progressive ESRD after non-acceptance 
to dialysis (20%; #5).The mean time to death from transplantation was 44.1 months 
(min – max: 1.0 – 74.0) One patient (#14) died early (first month) following a massive 
pulmonary embolism.Eight patients (53.3%) experienced a form of graft rejection during 
follow up and were appropriately treated. Of those with rejection, 6/8 (75.0%) had 
acute cellular rejection; 1 patient (12.5%; #7) experienced severe acute vascular 
rejection with loss of graft within 15 days post-transplantand another patient had 
antibody mediated rejection (12.5%; #10). Graft biopsies performed at variable times 
(usually for worsening of serum creatinine) during follow up showed confirmed 
rejection in these patients and in 2 other patients (#8 and #14) showed calcineurin 
inhibitor toxicity and BK virus infection in one patient (#11). Chronic allograft 
nephropathy was eventually identified in 3 patients ((#3, #5 and #9).Only one patient 
(#13) had recurrence of lupus nephritis (class V) in the graft.  
 
Discussion   
Although systemic lupus erythematosus is common in South Africa and possibly a 
common cause of early chronic kidney disease, the contribution of lupus nephritis to the 




more likely of all CKD patients to be on chronic immunosuppression, it is important to 
assess the outcome of LN patients following a kidney transplantation. To the best of our 
knowledge, this study is the first in the African continent to assess and report the 
outcomes of patients with ESRD secondary to LN transplanted in a single centre in Cape 
Town. 
The main findings of our study are: (i) increased mortality rate, particularly from sepsis, 
(ii) increased rejection rate and (iii) low recurrence of LN post-renal transplant. Patients 
with lupus nephritis may have received variable years and doses of various 
immunosuppression (particularly corticosteroids) before kidney transplant. Sepsis has 
been shown to be a common cause of death in LN patients related to cumulative dose 
of immunosuppression. Ayodele et al (from the same centre) in a retrospective outcome 
study of 105 patients with biopsy proven LN reported mortality in 32 patients (30.5%) 
with sepsis accounting for 37.5% of all mortality(26). Most patients in that study 
received cyclophosphamide and prednisone for induction and Azathioprine and 
prednisone for maintenancetherapy(26).Other authors have equally reported sepsis as 
major cause of mortality in LN patients as well as in renal transplant recipients(27-28-
29). Many of the patients in our study had a low HLA-PRA prior to renal transplant and 
thus were not excessively immunosuppressed at time of transplantation. This shows 
that LN patients still have a high risk of sepsis-related mortality following renal 
transplant, likely from cumulative years of receiving immunosuppression pre-transplant. 
Increased monitoring for infections is therefore required in these patients and measures 
to ensure infection prevention and control (e.g. adequate vaccination or use of 
prophylaxis) need to be put in place. In comparison to similar studies, mortality in this 
study was found to be much higher as others have reported mortality well below 20% 
from non-African countries (Table 4). 
In comparison to similar reports, we observed that graft rejection occurred quite 
frequently in our patients (53.3%) (Table 4). Golebiewska et al in a study from Poland 
reported occurrence of early acute rejection in33% of LN patients (compared to 21% 




year post-kidney transplant (30).Although we didn’t compare graft rejection rates in 
patients with LN compared to others in our study, it is still unclear why these patients 
had such a high frequency of acute rejection, especially as we can anecdotally report 
that medications adherence in our transplant clinics is very high. 
It is noted that despite the high rates of renal involvement and relapse in native kidneys, 
recurrent LN in a kidney allograft is often infrequent and when it occurs is relatively 
benign, without significant effects on patient and graft survival(31). One study that 
reported a high frequency of recurrence (54%) found only class I and II LN(32). 
Golebiewska et al only reported one patient with recurrent LN in their cohort (30). 
Recurrence of LN in our cohort was quite low and only occurred in one patient who 
developed proteinuria and was found to have class V LN on repeat biopsy. This shows 
that recurrence of disease (LN) should not be a major concern when patients are being 
worked up for a kidney transplant as it has not been demonstrated to be related to 
associated with graft or patient loss. 
The major limitations of the study are the retrospective design, heterogeneous 
characteristics of the recipients, low sample size andthus our inability to carry out 
survival analysis. Notwithstanding these limitations, this is the first study to report on 
the outcomes of transplanted patients with LN in the African setting and thus calls for 
further robust studies to improve our understanding of LN patient’s outcome post-
kidney transplant.  
Conclusion: 
This study shows that mortality in transplanted patients with LN is often due to 
infections and strategies to reduce the rate of sepsis in these patients need to be 
adequately addressed following kidney transplantation. We believe our findings provide 
further evidence that lupus is not a rare disease in South Africa, survival is not as good 
as in developed countries, recurrence of LN post transplantation is infrequent and 
causes of death are similar to those documented in other developing countries. Further 
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1 F C 2004 32 37 5 40.8 3.8 Cadaveric 4 148 
2 F C 2004 14 23.1 9.1 27.1 4.1 Cadaveric 4 47 
3 F C 2004 33 36.3 3.3 36.1 0.7 Cadaveric 4 66 
4 F C 2004 31 33.1 2.1 33.11 0.1 LRD 4 140 
5 F W 2005 17 19.2 2.2 22 2.8 Cadaveric 4 27 
6 F C 2005 25 27.1 2.1 35.8 8.7 Cadaveric 4 125 
7 F C 2006 33 37.1 4.1 39.8 2.7 Cadaveric 4 74 
8 M W 2007 21 34.4 13.4 38.9 4.5 LRD 4 99 
9 F C 2007 28 34.6 6.6 43.4 8.8 Cadaveric 4 102 
10 F B 2009 22.2 23.4 1.2 27.2 3.8 Cadaveric 4 86 
11 F B 2009 14 16.5 2.5 19.2 2.7 LRD 4 13 
12 F C 2009 38 46.3 8.3 49.1 2.8 Cadaveric 4 77 
13 F C 2010 24 29.7 5.7 30.1 0.4 Cadaveric 4 67 
14 F W 2011 25 29.3 4.3 33.2 3.9 LRD 4 1 
15 F B 2013 23 24.3 1.3 25.2 0.9 LRD 4 31 
 
F-Female; M-Male; C - Coloureds ; W – Whites; B – Blacks; SLE – systemic lupus reythematosus; ESRD – End-stage renal disease; Tx – Transplantation; LN – Lupus nephritis; 









Table 2: Combination of immunosuppressive drugs administered, HLA-immunological risk and Laboratory Data 












         CyA+Aza CyA+MMF Tacro+AZA Tacro+MMF 
1 F C CyA + MP 0% 316 17 131 41 N N Y N 
2 F C CyA + MP 0% 376 17 170 35 Y N N N 
3 F C CyA + MP 0% 85 70 100 58 Y N N N 
4 F C CyA + MP 0% 110 52 142 39 Y N N N 
5 F W CyA + MP 0% 95 68 230 25 Y N N N 
6 F C CyA + MP 0% 318 15 114 50 Y N N N 
7 F C CyA + MP 0% 790 5 1057 4 Y N N N 
8 M W CyA + MP 5% 123 60 104 73 N N N Y 
9 F C CyA + MP + AZA 0% 484 10 141 38 N N Y N 
10 F B CyA + MP 0% 907 6 98 75 N N N Y 
11 F B CyA + MP 0% 226 31 120 60 N N N Y 
12 F C CyA+ MP + AZA 2% 526 8 85 65 Y N N N 
13 F C CyA + MP 0% 187 29 92 66 N N N Y 
14 F W ATG 14% 699 6 - - N N N Y 
15 F B ATG 11% 92 83 71 111 N N N Y 
 
F-Female; M-Male; C - Coloureds ; W – Whites; B – Blacks; CyA – Cyclosporin; MP – Methy prednisone; AZA – Azathioprine; ATG – Anti-thymocyte globulin; MMF – 



















































1 F C HTN 124 41 N/A N/A N/A N/A N/A N/A 
2 F C ACR 1168 5 N/A Yes 1.92 Y 48.0 ACR 
3 F C ATN / CAN 908 5 N/A N/A N/A Y 66.0 N/A 
4 F C ACR 141 37 N/A N/A N/A N/A N/A ACR 
5 F W CAN 807 6 N/A Yes 2.0 Y 30.0 N/A 
6 F C ATN 241 19 N/A N/A N/A N/A N/A N/A 
7 F C AVR 396 11 N/A Yes 0.04 (15 
days) 
Y 74.0 AVR 
8 M W CNI 169 38 N/A N/A N/A N/A N/A N/A 
9 F C Borderline ACR / 
CAN 
95 54 N/A N/A N/A N/A N/A ACR 
10 F B ATN / AMR 102 54 N/A N/A N/A N/A N/A AMR 
11 F B BK Virus 130 50 N/A N/A N/A N/A N/A ACR 
12 F C N/A 82 67 N/A N/A N/A N/A N/A N/A 
13 F C ACR 119 45 Class V LN N/A N/A N/A N/A ACR 
14 F W CNI 193 26 N/A N/A N/A Y 1.0 ACR 
15 F B N/A 99 60 N/A N/A N/A N/A N/A N/A 
 
F-Female; M-Male; C - Coloureds ; W – Whites; B – Blacks; Bx: biopsy; Scr: serum creatinine; GFR: glomerular filtration rate; tx: transplant; LN: lupus nephritis; ESRD: end 
stage renal disease; F: female;    M: male; C: coloured; W: white; B: black; ; ATN: acute tubular necrosis; HTN – Hypertension; ACR – Acute cellular rejection; CAN – Chronic 








Table 4: Comparison of selected lupus-related renal transplant outcome studies 
Country Author (Ref) Year of publication Sample size Mean Age Gender (% f) Main donor type (%) Post-Tx ESRD (%) Rejection (%) Mortality (%) 
USA Chelamcharla et al 2007 2886 36.3± 10.8 82 Cadaveric 
(66) 
NR 34.9 58.4 
Poland Gołębiewska, et al 2016 19 40 ± 10 84.2 Cadaveric (94.7) 28.6 31.0 10.5 
Spain Cairoli et al 2014 40 36 ± 10.4 80 Cadaveric (58.0) NR 30.0 8.6 
Netherlands Deegens et al 2003 23 34±12 91.3 Cadaveric (78.2) 4.3 32.0 14 
Brazil Oliveira et al. 2012 14 33±9 85.7 Cadaveric (67.0) 8.3 50.0 5.6 
Iran Ghafari et al 2008 23 22.45±16 78.3 LRD (100) 31 NR 17 
South Africa Almradi et al 2017 15 25±10 93.3 Cadaveric (66.7) 20.0 53.3 33.3 
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• Quotes should be placed in single quotation marks: i.e. the respondent stated: '...' 
• Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
• If you wish material to be in a box, simply indicate this in the text. You may use the table 
format –this is the only exception. Please DO NOT use fill, format lines and so on. 
SAMJ is a generalist medical journal, therefore for articles covering genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and correct errors writ the above, although 
they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. ‘188del11’ can be 
glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
• Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
• HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
• OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
• Bennet et al. Standardized human pedigree nomenclature: Update and assessment of 
the recommendations of the National Society of Genetic Counsellors. J Genet Counsel 









• In Practice and Case reports 
• Reviews 
• Clinical trials 
• Correspondence 
• Obituaries 
• Book reviews 
• Guidelines  
Research 
Guideline word limit: 4 000 words 
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that clearly 
lay out the rationale for conducting the study. Some common reasons for conducting a study 
are: to fill a gap in the literature, a logical extension of previous work, or to answer an 
important clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods in as 
much detail as possible so that others would be able to replicate the study should they need to. 
Results should describe the study sample as well as the findings from the study itself, but all 




outcomes first before any secondary or tertiary findings or post-hoc analyses. The conclusion 
should briefly summarise the main message of the paper and provide recommendations for 
further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text. 
Structured abstract 
• This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published 
work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the 
intervention, primary and secondary outcomes, and any specific analyses that 
were done on the data. 
o Results: first sentence must be brief population and sample description; outline 
the results according to the methods described. Primary outcomes must be 
described first, even if they are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for 
further study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 





Guideline word limit: 1 000 words 
  
These opinion or comment articles are usually commissioned but we are happy to consider and 
peer review unsolicited editorials. Editorials should be accessible and interesting to readers 
without specialist knowledge of the subject under discussion and should have an element of 
topicality (why is a comment on this issue relevant now?) There should be a clear message to 
the piece, supported by evidence. 
Please make clear the type of evidence that supports each key statement, e.g.: 
• expert opinion 
• personal clinical experience 
• observational studies 
• trials 
• Systematic reviews. 
CME (by invite only) 
CME is intended to provide readers with practical, up-to-date information on medical and 
related matters. It is aimed at those who are not specialists in the field. 
From January 2016, all CME articles will be printed in full in the SAMJ. Please try to adhere 
strictly to the guidelines on word count as we have a page limit for the print issue of the SAMJ. 
We reserve the right to place some tables and reference lists online if this is necessary for 
space. 
In practice, this means that each CME topic usually covers two issues of the print issue of 
the SAMJ. 
The guest editor, in consultation with the editor, is responsible for convening a team of authors, 




suggestion is for 4 - 5 articles, although there is some room for flexibility contingent on 
discussions with the editor. 
For queries about these guidelines please feel free to contact the CME editor, Dr Bridget 
Farham, by email (ugqirha@iafrica.com) or telephone (+27 (0)21 789 2331). 
  
Review process 
The guest editor reviews the articles and returns them to the CME editor for review and final 
approval. 
Guest editorials 
Guideline word limit: 1 000 words 
• Include the guest editor’s personal details (qualifications, positions, affiliation, e-mail 
address, and a short personal profile (50words)). 
• If possible, include a photograph of the author(s) at high enough resolution for print. It 
is preferable to provide two guest editorials, one for each issue, so that the content of 
the articles in each issue is covered. 
Articles 
Guideline word limit: 2 000 - 3 000 words 
• Each article requires an abstract of ±200 words. 
• The editor reserves the right to shorten articles but will send a substantially shortened 
article back for author approval. 
Personal details 
Please supply: Your qualifications, position and affiliations and MP number (used for CPD 
points); Address, telephone number and fax number, and your e-mail address; and a short 





Guideline word limit: 2 000 - 3 000words 
This section includes articles that would previously have been accepted into the Forum section, 
and case reports. 
In practice articles are those that draw attention to specific issues of clinical, economic or 
political interest regarding medicine and healthcare in southern Africa. They are assigned to a 
topic: 
• Case report 
• Clinical practice 
• Clinical alert 
• Issues in medicine 
• Issues in public health 
• Healthcare delivery 
• Consensus/Position statement 
• Medicine and the environment 
• Medicine and the law 
• Cochrane corner 
  
 
An In Practice article should follow the following format – sub-headings are not necessary, but 
may be used for clarity: 
• Author affiliations and qualifications: to be the same as for Research. Provide all 




• Short abstract: does not need to be structured, but should capture the essential 
features of the article 
• Introduction: the reason for the article and the issue being addressed 
• Recent research, discussion, local policy around the issue – include your own research 
where appropriate 
• All statements should be referenced and, if opinion only, this should be stated 
• Discussion: how this article adds to the discussion around a particular topic 
• If a clinical practice or policy point is at issue, this needs to be emphasised, using a box 
with highlights if appropriate. 
  
Essentially In practice is an opportunity for a more discursive approach to topics of clinical, 
economic or political importance in southern African health systems. It is not an opportunity to 
put forward unsubstantiated opinions!  
Case reports 
The SAMJ has recently started to accept case reports. The cases must come from Africa, 
preferably southern Africa unless the condition is common to all African countries, and must be 
either a completely new description of a clinical condition or result (use Google!) or a case that 
highlights important practice or management issues. 
Please use the following format for case reports: 
• Title of case: do not include the words ‘a case report’ in the title 
• Summary/abstract:  up to 150 words summarising the case presentation and outcome 
• Background: why is this case important and why did you write it up? 
• Case presentation: presenting features, medical, social, family history as appropriate 




• Investigations, if relevant: save space by simply saying ‘normal’ if, for example, renal 
function was completely normal, rather than listing normal results, highlight the 
abnormal – or indeed the normal if this is clinically significant 
• Differential diagnosis, if relevant 
• Treatment, if relevant 
• Outcome and follow-up 
• Discussion – a VERY BRIEF review of similar published cases 
• Teaching points: 3 - 5 bullet points 
• References: as per the SAMJ house style 
• Tables and figures: keep to a minimum. Use clinical images where relevant – we need hi-
res versions for print, and identifiable persons must have a consent form 
• Patient consent: please include a statement about patient consent to a written case 
report. This should be uploaded as a supplementary file. 
Clinical trials 
Guideline word limit: 4000 words 
As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an intervention, 
with or without a concurrent comparison/control group to study the cause-and-effect 
relationship between the intervention and health outcomes. All clinical trials should be 
registered with the appropriate national clinical trial registry (or any international primary 
register, if relevant), and the trial registration number should be cited at the end of the 
abstract. Since 1st December 2005, all clinical trials conducted in South Africa have been 
required to be registered in the South African National Clinical Trials Register. 




at or before the time of first patient enrolment as a condition for publication. The trial registry 
name and registration number must be included in the manuscript. 
Please refer to the general guidelines for all papers at the top of this article for additional 
requirements with respect to ethics approval, funding, author contributions, etc. The format of 
original research articles should be followed for reporting of clinical trial results. 
Review articles 
Guideline word limit: 4 000 words 
These are welcome, but should be either commissioned or discussed with the Editor before 
submission. A review article should provide a clear, up-to-date account of the topic and be 
aimed at non-specialist hospital doctors and general practitioners. 
Please ensure that your article includes: 
• Abstract: unstructured, of about 100-150 words, explaining the review and why it is 
important 
• Methods: Outline the sources and selection methods, including search strategy and 
keywords used for identifying references from online bibliographic databases. Discuss 
the quality of evidence. 
• When writing: clarify the evidence you used for key statements and the strength of the 
evidence. Do not present statements or opinions without such evidence, or if you have 
to, say that there is little or no evidence and that this is opinion. Avoid specialist jargon 
and abbreviations, and provide advice specific to southern Africa. 
• Personal details: Please supply your qualifications, position and affiliations and MP 
number (used for CPD points); address, telephone number and fax number, and your e-
mail address; and a short personal profile (50 words) and a few words about your 
current fields of interest. 




Guideline word limit: 500 words 
Letters to the editor should relate either to a paper or article published by the SAMJ or to a 
topical issue of particular relevance to the journal’s readership 
• May include only one illustration or table 
• Must include a correspondence address. 
Book reviews 
Guideline word limit: 400 words 
Should be about 400 words and must be accompanied by the publication details of the book. 
Provide a hi-res image of the cover if possible (with permission from the copyright holder). 
Obituaries 
Guideline word limit: 400 words 
Should be offered within the first year of the practitioner’s death, and may be accompanied by 
a photograph. 
Guidelines  
Guidelines should always be discussed with the Editor prior to submission. 
Because of the intensive review process required to ensure Guidelines are independent, 
evidence-based and free from commercial bias, they are usually published as a supplement to 
the SAMJ, the costs of which must be covered by sponsorship, advertising or payment by the 
guideline authors/association. We will provide a quote based on the expected length of the 
guideline and whether it is to appear online only, or in print, which must be accepted by the 
body putting the guidelines together before submitting the work to the SAMJ. 
The Editor reserves the right to determine the scheduling of supplements. Understandably, a 
delay in publication must be anticipated dependent upon editorial workflow. 




Please access this website before putting the guidelines together, download the Agree 11 
instrument and use this to put the guidelines together. 
All submitted guidelines will be sent to the local Agree II appraisal committee for review and 
must be endorsed by an appropriate body prior to consideration and all conflicts of interest 
expressed. 
A structured abstract not exceeding 400 words (recommended sub-headings: Background, 
Recommendations, Conclusion) is required. Sections and sub-sections must be numbered 
consecutively (e.g. 1. Introduction; 1.1 Definitions; 2.etc.) And summarised in a Table of 
Contents. 
Illustrations/photos/scans 
• If illustrations submitted have been published elsewhere, the author(s) should provide 
consent to republication obtained from the copyright holder. 
• Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
• Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full). 
• All images must be of high enough resolution/quality for print. 
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
• Ensure all graph axes are labelled appropriately, with a heading/description and units 
(as necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 
3.0; 4.0 etc. 
• Scans/photos showing a specific feature e.g. intermediate magnification micrograph of a 
low malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an arrow 
to show the tumour. 
• Each image must be attached individually as a 'supplementary file' upon submission (not 







• Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
• Large tables will generally not be accepted for publication in their entirety. Please 
consider shortening and using the text to highlight specific important sections, or offer a 
large table as an addendum to the publication, but available in full on request from the 
author 
• Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
• Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to consecutively 
in the text. 
• Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
• Ensure each table has a concise title and column headings, and include units where 
necessary. 
• Footnotes must be indicated with consecuUve use of the following symbols: * † ‡ § ¶ || 
then ** †† ‡‡ etc. 
Do not: Use [Enter] within a row to make ‘new rows’: 
Rather: 
Each row of data must have its own proper row: 
Do not: use separate columns for n and %: 
Rather: 
Combine into one column, n (%): 





Use <> symbols or numbers that don’t overlap: 
References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Endnotes must not be used. 
• Authors must verify references from original sources. 
• Citations should be inserted in the text as superscript numbers between square 
brackets, e.g. These regulations are endorsed by the World Health Organization,[2] and 
others.[3,4-6] 
• All references should be listed at the end of the article in numerical order of appearance 
in the Vancouver style (not alphabetical order). 
• Approved abbreviations of journal titles must be used; see the List of Journals in Index 
Medicus. 
• Names and initials of all authors should be given; if there are more than six authors, the 
first three names should be given followed by et al. 
• Volume and issue numbers should be given. 
• First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
• Wherever possible, references must be accompanied by a digital object identifier (DOI) 
link). Authors are encouraged to use the DOI lookup service offered by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
o Look for the correct, matching article in the list of results. 
o Click Actions > Cite 




o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
  
  
From submission to acceptance 
Submission and peer-review 
To submit an article: 
• Please ensure that you have prepared your manuscript in line with the SAMJ 
requirements. 
• All submissions should be submitted via Editorial Manager 
• The following are required for your submission to be complete: 
o Anonymous manuscript (unless otherwise stated) 
o Author Agreement form 
o Manuscript 
o Any supplementary files: figures, datasets, patient consent form, permissions for 
published images, etc. 
• Once the submission has been successfully processed on Editorial Manager, it will 
undergo a technical check by the Editorial Office before it will be assigned to an editor 
who will handle the review process. If the author guidelines have not been 
















The following process should usually take between 4 - 6 weeks: 
1. An accepted manuscript is passed to a Managing Editor to assign to a copyeditor (CE). 
2. The CE copyedits in Word, working on house style, format, 
spelling/grammar/punctuation, sense and consistency, and preparation for typesetting. 
3. If the CE has an author queries, he/she will contact the corresponding author and send 
them the copyedited Word doc, asking them to solve the queries by means of track 




4. The authors are typically asked to respond within 1-3 days. Any comments/changes 
must be clearly indicated e.g. by means of track changes. Do not work in the original 
manuscript - work in the copyedited file sent to you and make your changes clear. 
5. The CE will finalise the article and then it will be typeset. 
6. Once typeset, the CE will send a PDF of the file to the authors to complete their final 
check, while simultaneously sending to the 2nd-eye proof-reader. 
7. The authors are typically asked to complete their final check and sign-off within 1-2 
days. No major additional changes can be accommodated at this point. 
8. The CE implements the authors’ and proof-reader’s mark-ups, finalises the file, and 
prepares it for the upcoming issue. 
Changing contact details or authorship 
Please notify the Editorial Department of any contact detail changes, including email, to 
facilitate communication. 
Publication 
Online v. print 
The SAMJ is an online journal. The online version of the journal is the one that has the widest 
circulation, is indexed by bibliographic databases including PubMed and SciELO, and is 
accessible in academic libraries. A printed edition, containing material selected by the Editor is 
also published each month and distributed to the membership of the South African Medical 
Association. 
Online 
• The full text of all accepted articles is published in full online, open access, within 4 - 6 
weeks of acceptance. 




• You may want to make use of the advantages of online publication e.g. specify web links 
to other sources, images, data or even a short video. 
Print 
• Not all articles will be selected for print. 
• An article may be selected for print in a different month from that in which it was 
published online. 
• Research articles will appear in abstract form only, if selected for a print edition. 
Errata and retractions 
Errata 
Should you become aware of an error or inaccuracy in yours or someone else’s contribution 
after it has been published, please inform us as soon as possible via an email to 
publishing@hmpg.co.za,including the following details: 
• Journal, volume and issue in which published 
• Article title and authors 
• Description of error and details of where it appears in the published article 
• Full detail of proposed correction and rationale 
We will investigate the issue and provide feedback. If appropriate, we will correct the web 
version immediately, and will publish an erratum in the next issue. The correction will be 
indexed, as PubMed has a function for linking errata back to the original article. All 
investigations will be conducted in accordance with guidelines provided by the Committee on 






Retraction of an article is the prerogative of either the original authors or the editorial team of 
HMPG. Should you wish to withdraw your article before publication, we need a signed 
statement from all the authors. 
Should you wish to retract your published article, all authors have to agree in writing before 
publication of the retraction. 
Send an email to publishing@hmpg.co.za, including the following details: 
• Journal, volume and issue to which article was submitted/in which article was published 
• Article title and authors 
• Description of reason for withdrawal/retraction. 
We will make a decision on a case-by-case basis upon review by the editorial committee in line 
with international best practices. Comprehensive feedback will be communicated with the 
authors with regard to the process. In case where there is any suspected fraud or professional 
misconduct, we will follow due process as recommended by the Committee on Publication 
Ethics (COPE), and in liaison with any relevant institutions. 
When a retraction is published, it will be linked to the original article. 
Indexing 
The SAMJ has an impact factor of 1.5. 
Published articles are covered by the following major indexing services. As such articles 
published in the SAMJ are immediately available to all users of these databases, guaranteed a 
global and African audience: 
• Index Medicus (Medline/PubMed)  
• ExcerptaMedica (EMBASE) 
• Biological Abstracts (BIOSIS) 












Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc.  
Submission Preparation Checklist 
As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors that do 
not adhere to these guidelines. 
1. Named authors consent to publication and meet the requirements of authorship as set 
out by the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. 
3. The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4. The manuscript is in Microsoft Word document format. The text is single-spaced, in 12-




5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (PDF or jpeg). These must be submitted individually as 'supplementary files' (not 
solely embedded in the manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 
10. Any conflict of interest (or competing interests) is indicated by the author(s). 
Copyright Notice 
Copyright of published material remains in the Authors’ name. This allows authors to use their 
work for their own non-commercial purposes without seeking permission from the Publisher, 
subject to properly acknowledging the Journal as the original place of publication. 
 Authors are free to copy, print and distribute their articles, in full or in part, for teaching 
activities, and to deposit or include their work in their own personal or institutional database or 
on-line website. Authors are requested to inform the Journal/Publishers of their 
desire/intention to include their work in a thesis or dissertation or to republish their work in 
any derivative form (but not for commercial use).  
 Material submitted for publication in the SAMJ is accepted provided it has not been published 
or submitted for publication elsewhere. Please inform the editorial team if the main findings of 
your paper have been presented at a conference and published in abstract form, to avoid 
copyright infringement. 
Privacy Statement 
The SAMJ is committed to protecting the privacy of the users of this journal website. The 




the stated purposes of this journal and will not be made available to third parties without the 
user’s permission or due process. Users consent to receive communication from the SAMJ for 
the stated purposes of the journal. Queries with regard to privacy may be directed 
to publishing@hmpg.co.za. 
 
 
 
